These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 3009944

  • 1. Biochemical and pharmacological analysis of 2-[(2-dimethylaminobenzyl)sulfinyl] benzimidazole (NC-1300), a new proton pump inhibitor.
    Okabe S, Higaki E, Higuchi T, Sato M, Hara K.
    Jpn J Pharmacol; 1986 Feb; 40(2):239-49. PubMed ID: 3009944
    [Abstract] [Full Text] [Related]

  • 2. Effects of a new benzimidazole derivative, NC-1300-O-3, on gastric secretion and gastroduodenal lesions in rats.
    Okabe S, Akimoto Y, Yamasaki S, Kuwahara K.
    Jpn J Pharmacol; 1991 Apr; 55(4):477-91. PubMed ID: 1832198
    [Abstract] [Full Text] [Related]

  • 3. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
    Yamaguchi T, Aihara K, Yamada S, Narita S, Kogi K.
    Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological properties of a new proton pump inhibitor, 2-amino-4,5-dihydropyrido[1,2-a]thiazolo [5,4-g] benzimidazole (YJA20379-5).
    Sohn SK, Chang MS, Chung YK, Kim KB, Wook TW, Kim SG, Choi WS.
    Arch Pharm Res; 1998 Jun; 21(3):241-7. PubMed ID: 9875438
    [Abstract] [Full Text] [Related]

  • 5. Effects of NC-1300-B, a new benzimidazole derivative, on hog gastric H+, K+-ATPase, gastric acid secretion and HCl.ethanol-induced gastric lesions in rats.
    Okabe S, Akimoto Y, Yamasaki S, Nagai H.
    Dig Dis Sci; 1988 Nov; 33(11):1425-34. PubMed ID: 2846250
    [Abstract] [Full Text] [Related]

  • 6. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
    Kim KB, Chang MS, Chung YK, Sohn SK, Kim SG, Choi WS.
    J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
    [Abstract] [Full Text] [Related]

  • 7. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
    Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N, Maki Y.
    J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
    [Abstract] [Full Text] [Related]

  • 8. [Effects of gastric proton pump inhibitors on gastric secretion and peptic ulcers].
    Okabe S.
    Nihon Yakurigaku Zasshi; 1986 Apr; 87(4):351-60. PubMed ID: 2873085
    [Abstract] [Full Text] [Related]

  • 9. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD.
    Arzneimittelforschung; 2001 Apr; 51(3):204-13. PubMed ID: 11304936
    [Abstract] [Full Text] [Related]

  • 10. The biochemical and pharmacological properties of a newly synthesized H+-K+ ATPase inhibitor, 2-dimethylamino-4,5-dihydrothiazolo[4,5:3,4]pyridol-[1,2-a]benzimidazol e.
    Chung YK, Chang MS, Kim KB, Sohn SK, Woo TW, Lee SB, Choi WS.
    Can J Physiol Pharmacol; 1998 Sep; 76(9):921-9. PubMed ID: 10066143
    [Abstract] [Full Text] [Related]

  • 11. [Discovery and development of the proton pump inhibitor].
    Igata H, Okabe S.
    Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
    [Abstract] [Full Text] [Related]

  • 12. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
    Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N.
    Biochem Pharmacol; 1991 Jul 05; 42(2):321-8. PubMed ID: 1650210
    [Abstract] [Full Text] [Related]

  • 13. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y.
    J Pharm Pharmacol; 1999 Apr 05; 51(4):457-64. PubMed ID: 10385219
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
    Wallmark B, Lorentzon P, Larsson H.
    Scand J Gastroenterol Suppl; 1985 Apr 05; 108():37-51. PubMed ID: 2988109
    [Abstract] [Full Text] [Related]

  • 17. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
    Nagaya H, Inatomi N, Satoh H.
    Jpn J Pharmacol; 1991 Apr 05; 55(4):425-36. PubMed ID: 1886288
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats.
    Yamamoto O, Okada Y, Okabe S.
    Dig Dis Sci; 1984 May 05; 29(5):394-401. PubMed ID: 6714055
    [Abstract] [Full Text] [Related]

  • 20. Cytoprotective effect of NC-1300-O-3 against gastric lesions induced by necrotizing agents in rats.
    Matsukura H, Masuda M, Kawaguchi K, Uchida A, Kamishiro T.
    Jpn J Pharmacol; 1994 May 05; 65(1):9-18. PubMed ID: 8089937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.